Abstract:Multiple plant (fruits, vegetables) and spice (turmeric)-derived natural products, which have pleiotropic activities (anti-inflammatory, antioxidant, anti-apoptotic, neurogenic) are also neuroprotective in vitro against numerous chemical insults and promote behavioral recovery in vivo following embolic strokes. We have focused on 2 types of natural products: 1) curcumin-based compounds such as CNB-001 and 2) flavone-based compounds such as fisetin and baicalein. We have synthesized a new library of flavonoid molecules to improve their pharmacological characteristics and have selected candidates using a battery of vitro screening assays with stringent criteria: 1) HT22 hippocampal cell survival (in vitro ischemia model using 20μM iodoacetic acid); 2) primary mouse cortical neurons cell survival (in vitro excitotoxicity assay using 10μM glutamate); 3) HT22 hippocampal cell survival assay (oxytosis using 5 mM glutamate to induce non-NMDA mediated cell death due to the absence of NMDA receptors on HT22 cells). EC50 ≤ 100 nM and survival ≥80% in the IAA assay, ≥35% survival in the cortical neuron assay and EC 50 ≤ 300 nM and ≥50% survival in the oxytosis assay. All compounds were screened in triplicate using concentrations up to 10 μM. We chemically modified fisetin to improve its potency, increase blood brain barrier penetration (CLogP, an indicator of blood brain barrier penetration) and reduce tPSA (topographical polar surface area). We have developed a structure activity relationship (SAR) indicating that the absence of a hydroxyl group on the A ring of fisetin enhances its potency. Two compounds PM-001 and PM-004) are 6 fold more potent than fisetin. Altering a hydroxyl group at the 3-position of the B ring has no impact on activity. The addition of multiple hydrophobic groups to various positions on the A ring, such as the addition of methyl groups at the 6 and/or 7 position improved potency ∼10-100 fold over fisetin (e.g. compound PM-010) while the addition of a more hydrophobic naphthalene group (PM-002) and (PM-003) improved the potency ∼40 fold over fisetin and increased the ClogP and reduced the tPSA. SAR studies on the C ring suggested that hydrogen bond accepting groups such as a methoxy at the 4' position and a hydrogen bond donating group such as a hydroxyl at the 3' position further enhanced potency. For example compound CMS-064, CMS-069 and CMS-092 are some of the most potent compounds, with EC 50 s below 40 nM. These compounds also have CLogPs and tPSAs consistent with enhanced brain penetration. In conclusion, we have used a rational medicinal chemistry approach in combination with in vitro screening analysis to identify new flavonoid molecules to optimally promote neuroprotection. The molecules which will be discussed in detail are being further characterized and de-risked to treat stroke.

Fibroblast growth factor receptor modulators employing diamines with reduced phospholipidosis-inducing potential

Discovery of 1,2,3-triazole-based fibroblast growth factor receptor modulators

Mangostanin Derivatives as Novel and Orally Active Phosphodiesterase 4 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis with Improved Safety

The Prodrug of 7,8-Dihydroxyflavone Development and Therapeutic Efficacy for Treating Alzheimer's Disease.

Lipidation-dimerization Platform Unlocks Treatment Potential of Fibroblast Growth Factor 21 for Non-Alcoholic Steatohepatitis

Abstract 2324: Translational Stroke Research: Identification Of A Novel Family Of Natural Product Derived Flavonoid-Based Polyphenols With Potent Pleiotropic Neuroprotective Activity.

Discovery of novel brain-penetrant GluN2B NMDAR antagonists via pharmacophore-merging strategy as anti-stroke therapeutic agents

Systemic treatment with a novel basic fibroblast growth factor mimic small-molecule compound boosts functional recovery after spinal cord injury

Design, Synthesis and Biological Evaluation of a Series of Novel 2-Benzamide-4-(6-oxy-n-methyl-1-naphthamide)-pyridine Derivatives As Potent Fibroblast Growth Factor Receptor (FGFR) Inhibitors

Targeting Lewy body dementia with neflamapimod‐rasagiline hybrids

Synthesis and Preclinical Characterization of LY3154885, a Human Dopamine D1 Receptor Positive Allosteric Modulator with an Improved Nonclinical Drug-Drug Interaction Risk Profile.

Discovery of N-(5-amido-2-methylphenyl)-5-methylisoxazole-3-carboxamide as dual CSF-1R/c-Kit Inhibitors with improved stability and BBB permeability

(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitors with Broad Antiproliferative Activity Against Tumor Cells

Discovery of 1,8-naphthalidine derivatives as potent anti-hepatic fibrosis agents via repressing PI3K/AKT/Smad and JAK2/STAT3 pathways

1,3-Benzodioxole-based Fibrate Derivatives As Potential Hypolipidemic and Hepatoprotective Agents.

Design, synthesis, and evaluation of n-butylphthalide and ligustrazine hybrids as potent neuroprotective agents for the treatment of ischemic stroke in vitro and in vivo

Fiscalin Derivatives as Potential Neuroprotective Agents

Structural Optimization of Fibroblast Growth Factor Receptor Inhibitors for Treating Solid Tumors

Discovery of 2,4-Diarylaminopyrimidine Derivatives Bearing Sulfonamide Moiety As Novel FAK Inhibitors

Design and Synthesis of 5-Aminopyrazole and 5-Aminotriazole Derivatives As Fibroblast Growth Factor Receptor Inhibitors

Phosphorus Dendrimers Co-deliver Fibronectin and Edaravone for Combined Ischemic Stroke Treatment via Cooperative Modulation of Microglia/Neurons and Vascular Regeneration